Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Change in Acquisitions & Divestments (2016 - 2025)

Historic Change in Acquisitions & Divestments for Rocket Pharmaceuticals (RCKT) over the last 9 years, with Q3 2025 value amounting to $123.0 million.

  • Rocket Pharmaceuticals' Change in Acquisitions & Divestments rose 2321.32% to $123.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $376.2 million, marking a year-over-year increase of 187.59%. This contributed to the annual value of $383.5 million for FY2024, which is 2396.44% up from last year.
  • As of Q3 2025, Rocket Pharmaceuticals' Change in Acquisitions & Divestments stood at $123.0 million, which was up 2321.32% from $84.5 million recorded in Q2 2025.
  • Rocket Pharmaceuticals' Change in Acquisitions & Divestments' 5-year high stood at $123.0 million during Q3 2025, with a 5-year trough of $38.3 million in Q4 2021.
  • In the last 5 years, Rocket Pharmaceuticals' Change in Acquisitions & Divestments had a median value of $82.0 million in 2022 and averaged $80.4 million.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first soared by 24787.3% in 2021, then crashed by 2396.59% in 2023.
  • Over the past 5 years, Rocket Pharmaceuticals' Change in Acquisitions & Divestments (Quarter) stood at $38.3 million in 2021, then soared by 32.7% to $50.8 million in 2022, then skyrocketed by 42.35% to $72.3 million in 2023, then grew by 19.54% to $86.5 million in 2024, then soared by 42.22% to $123.0 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $123.0 million for Q3 2025, versus $84.5 million for Q2 2025 and $82.3 million for Q1 2025.